Bone-Targeted Therapy in Metastatic Breast Cancer – All Well-Established Knowledge?

Breast care

Simon P. Gampenrieder¹  Richard Greil¹  Gabriel Rinnerthaler¹ 

[1] IIIrd Medical Department with Hematology, Medical Oncology, Hemostaseology, Infectious Diseases and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute (SCRI) with Laboratory of Immunological and Molecular Cancer Research (LIMCR) and Center for Clinical Cancer and Immunology Trials (CCCIT), Paracelsus Medical University Salzburg, Salzburg, Austria

关键词: Metastatic breast cancer;    Bone metastasis;    Bone-targeted therapy;    Bisphosphonates;    Denosumab;   

DOI  :  10.1159/000368710

学科分类：泌尿医学

来源: S Karger AG

【 摘 要 】

Bone-targeted therapies like bisphosphonates (zoledronic acid or pamidronate) or denosumab are recommended in all patients with metastatic breast cancer and bone metastases, whether they are symptomatic or not. The choice between these 2 different agents, however, remains open. In this review, we critically discuss the emerging evidence for direct anti-tumor activity of bone-targeting agents, the utility of bone turnover markers for treatment decision and efficacy prediction, as well as the safety and financial aspects of bisphosphonates and denosumab. Furthermore, we provide a possible therapeutic algorithm, and present new pharmacologic agents which are being investigated for the treatment of metastatic bone disease.

【 授权许可】

Unknown